Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial
Authors:
- Zepeng MuZMZepeng Mu
- Wei WangWWWei Wang
- Jing WangJWJing Wang
- Wenshan LvWLWenshan Lv
- Ying ChenYCYing Chen
- Fang WangFWFang Wang
- Xiaolong YuXYXiaolong Yu
- Yangang WangYWYangang Wang
- Bingfei ChengBCBingfei Cheng
- Zhongchao WangZWZhongchao Wang
- 13 August 2019
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 38 (12) , 3511-3519
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Predicting Response or Non-response to Urate-Lowering Therapy in Patients with GoutCurrent Rheumatology Reports, 2018
- A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The NetherlandsClinical Rheumatology, 2018
- Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993-2011JAMA, 2016
- Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-AnalysisDrugs, 2016
- Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective AnalysisRheumatology and Therapy, 2016
- Adherence and persistence to urate-lowering therapies in the Irish settingClinical Rheumatology, 2014
- Gout, Urate‐Lowering Therapy, and Uric Acid Levels Among Adults in the United StatesArthritis Care & Research, 2014
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008Arthritis & Rheumatism, 2011
- Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trialArthritis Care & Research, 2008